Trial Profile
A Phase IV, Open-label, Multicenter and Single-arm on the Immunogenicity of Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs V 503 (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- Acronyms GESIDA 10017
- 24 Aug 2023 Planned End Date changed from 15 Dec 2021 to 14 Jul 2021.
- 24 Aug 2023 Planned primary completion date changed from 15 Dec 2020 to 14 Jul 2021.
- 24 Aug 2023 Status changed from active, no longer recruiting to completed.